# Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer

> **NCT01198535** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Colon Mucinous Adenocarcinoma
- Colon Signet Ring Cell Adenocarcinoma
- Rectal Mucinous Adenocarcinoma
- Rectal Signet Ring Cell Adenocarcinoma
- Recurrent Colon Carcinoma
- Recurrent Rectal Carcinoma
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Gamma-Secretase Inhibitor RO4929097
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01198535
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2012-07
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01198535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01198535, "Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01198535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*